MatthewJBarthMD

PubMed

• 87 citations
  Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R
  Lisa Giulino-Roth, Tara O'Donohue, Zhengming Chen, Nancy L. Bartlett, Ann S. LaCasce, William Martin-Doyle, Matthew J. Barth, Kimberly Davies, Kristie A. Blum, Beth A....> ;British Journal of Haematology. 2017 Dec 1
• 49 citations
  Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
  Lisa Giulino-Roth, Herman van Besien, Tanner Dalton, Jennifer Totonchy, Anna Rodina, Tony Taldone, Alexander Bolaender, Hediye Erdjument-Bromage, Jouliana Sadek, Amy C...> ;Molecular Cancer Therapeutics. 2017 Jun 15
• 12 citations
  Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection – a review
  Lynda K. Beaupin, Bruce Bostrom, Matthew J. Barth, Irene Franklin, Raven Jaeger, Priyanka Kamath, Brian Schreiber, Archie Bleyer> ;Leukemia & Lymphoma. 2017 Apr 1
• 13 citations
  Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
  Matthew J. Barth, Yaya Chu, Patrick J. Hanley, Mitchell S. Cairo> ;British Journal of Haematology. 2016 May 1
• 68 citations
  Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituxima...
  Aradhana Awasthi, Janet Ayello, Carmella van de Ven, Mona Elmacken, Anthony Sabulski, Matthew J. Barth, Myron S. Czuczman, Humayun Islam, Christian Klein, Mitchell S. ...> ;British Journal of Haematology. 2015 Oct 16
• 34 citations
  Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
  Sarah Frys, Zachary Simons, Matthew J. Barth, Juan J Gu, Cory Mavis, Joseph J. Skitzki, Liu Song, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri> ;British Journal of Haematology. 2015 May 1
• 8 citations
  Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot...
  Bruce Shiramizu, Stanton Goldman, Lynette M. Smith, Melissa Agsalda-Garcia, Paul J. Galardy, Sherrie L. Perkins, J. Kimble Frazer, Warren G. Sanger, James R. Anderson,...> ;British Journal of Haematology. 2015 Aug 1
• 124 citations
  Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
  Yaya Chu, Jessica Hochberg, Ashlin Yahr, Janet Ayello, Matthew J. Barth, Myron S. Czuczman, Mitchell S. Cairo> ;Cancer Immunology Research. 2015 Apr 1
• 94 citations
  Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children’s Oncology Group...
  Stanton Goldman, Lynette M. Smith, Paul J. Galardy, Sherrie L. Perkins, John Kimble Frazer, Warren G. Sanger, James R. Anderson, Thomas G. Gross, Howard J. Weinstein, ...> ;British Journal of Haematology. 2014 Nov 1
• 24 citations
  Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.
  Matthew J. Barth, Stanton Goldman, Lynette M. Smith, Sherrie L. Perkins, Bruce Shiramizu, Thomas G. Gross, Lauren Harrison, Warren G. Sanger, Mark B. Geyer, Lisa Giuli...> ;British Journal of Haematology. 2013 Sep 1
• 16 citations
  The future role of monoclonal antibody therapy in childhood acute leukaemias
  Matthew J. Barth, Elizabeth A. Raetz, Mitchell S. Cairo> ;British Journal of Haematology. 2012 Oct 1
• 109 citations
  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.
  S. Goldman, Lynette M. Smith, James R. Anderson, Sherrie L. Perkins, Lauren Harrison, Mark B. Geyer, Thomas G. Gross, Howard J. Weinstein, Sharon Bergeron, Bruce Shira...> ;Leukemia. 2013 Apr 1
• Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
  Barth, M. J., Hernandez-Ilizaliturri, F. J., Mavis, C., Tsai, P. C., Gibbs, J. F., Deeb, G., Czuczman, M. S.> ;Br J Haematol. 2012 Feb
• 48 citations
  Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program.
  Dawn L. DeMeo, Christoph Lange, Edwin K. Silverman, Jody M. Senter, Jeffrey M. Drazen, Matthew J. Barth, Nan M. Laird, Scott T. Weiss> ;Genetic Epidemiology. 2002 Nov 1
• 86 citations
  Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease: airflow obstruction and chronic bronchitis phenotypes
  Edwin K. Silverman, Jonathan D. Mosley, Lyle J. Palmer, Matthew J. Barth, Jody M. Senter, Alison Brown, Jeffrey M. Drazen, David J. Kwiatkowski, Harold A. Chapman, Edw...> ;Human Molecular Genetics. 2002 Mar 15
• Join now to see all

Lectures

• High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018